Testing effectiveness (Phase 2)Study completedNCT00792025
What this trial is testing
Sunitinib as Second-Line Therapy in Treating Patients With Locally Advanced or Metastatic Transitional Cell Cancer
Who this might be right for
Bladder CancerTransitional Cell Cancer of the Renal Pelvis and Ureter
Institut Curie 80